Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 10, 2014, Pages 908-915

  Ohta, Takashi ^a   Kim, Young Ho ^a,e   Oh, Ji Eun ^a   Satomi, Kaishi ^a   Nonoguchi, Naosuke ^a   Keyvani, Kathy ^g   Pierscianek, Daniela ^g   Sure, Ulrich ^g   Mittelbronn, Michel ^h   Paulus, Werner ^f   Vital, Anne ^d   Yokoo, Hideaki ⁱ   McDonald, Kerrie ^j   Kleihues, Paul ^j,k   Nazaret, Nicolas ^b   Barbet, Fabienne ^b   Lachuer, Joel ^b,c   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^e National Cancer Center   (South Korea)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h GOETHE UNIVERSITY   (Germany)

ⁱ GUNMA UNIVERSITY   (Japan)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k UNIVERSITY OF ZURICH   (Switzerland)

more..

Author keywords

ERCC1; Exome sequencing; Gemistocytic astrocytoma; Glioma; Homozygous deletion; RRAS

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; ISOCITRATE DEHYDROGENASE; PROTEIN; RRAS PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RAS PROTEIN; RRAS PROTEIN, HUMAN;

ADULT; ARTICLE; ASTROCYTOMA; CHROMOSOME 19Q; CHROMOSOME LOSS; CONTROLLED STUDY; EXOME; FEMALE; GEMISTOCYTIC ASTROCYTOMA; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROTEIN METHYLATION; SURVIVAL RATE; VIRUS ONCOGENE; BRAIN NEOPLASMS; CHROMOSOME 19; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; TRENDS;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 19; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; RAS PROTEINS; SURVIVAL RATE;

EID: 84913601881     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000110     Document Type: Article

References (52)

1. Louis DN, Ohgaki H, Wiestler OD, CaveneeWK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC, 2007
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
4. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53
5. Peraud A, Kreth FW, Wiestler OD, et al. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002;8:1117-24
6. Watanabe K, Tachibana O, Yonekawa Y, et al. Role of gemistocytes in astrocytoma progression. Lab Invest 1997;76:277-84
7. Watanabe K, Ogata N, von Ammon K, et al. Immunohistochemical assessments of P53 protein accumulation and tumor growth fraction during the progression of astrocytomas. In: Nagai M, ed. Brain Tumour Research and Therapy. Tokyo, Japan: Springer-Verlag, 1996;255-62
8. Watanabe K, Peraud A, Gratas C, et al. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 1998;95:559-64
9. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49-56
10. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177:2708-14
11. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-7
12. Nonoguchi N, Ohta T, Oh JE, et al. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013;126:931-37
13. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-53
14. Nigro JM, TakahashiMA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001;158:1253-62
15. Fujisawa H, Reis RM, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72
16. Nakamura M, Yang F, Fujisawa H, et al. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 2000; 59:539-43
17. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002;103:267-75
18. Lv SQ, Kim YH, Giulio Fet al. Genetic alterations in microRNAs in medulloblastomas. Brain Pathol 2012;22:230-39
19. Liu ZG, Chen HY, Cheng JJ, et al. Relationship between methylation status of ERCC1 promoter and radiosensitivity in glioma cell lines. Cell Biol Int 2009;33:1111-17
20. Park G, Gim J, Kim AR, et al. Multiphasic analysis of whole exome sequencing data identifies a novel mutation of ACTG1 in a nonsyndromic hearing loss family. BMC Genomics 2013;14:191
21. Rubio MP, Correa KM, Ueki K, et al. The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 1994;54:4760-63
22. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52
23. Chen HY, Shao CJ, Chen FR, et al. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer 2010;126:1944-54
24. Kros JM, SchoutenWC, Janssen PJ, et al. Proliferation of gemistocytic cells and glial fibrillary acidic protein (GFAP)-positive oligodendroglial cells in gliomas: AMIB-1/GFAP double labeling study. Acta Neuropathol 1996; 91:99-103
25. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
26. Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 2012; 109:15-22
27. Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 2012;118:452-60
28. Okita Y, Narita Y, Miyakita Y, et al. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol 2012; 41:1325-36
29. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16: 1597-604
30. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-54
31. Dubbink HJ, Taal W, van MR, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009;73:1792-95
32. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-26
33. Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013;126: 267-76
34. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61
35. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009;15:330-37
36. Fujisawa H, Kurrer M, Reis RM, et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with LOH on chromosome 10q25-qter. Am J Pathol 1999;155:387-94
37. Arslantas A, Artan S, Oner U, et al. Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 2007;13:39-46
38. Nishizaki T, Ozaki S, Harada K, et al. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer 1998;21:340-46
39. Watanabe T, Yokoo H, Yokoo M, et al. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 2001;60:1181-89
40. Marte BM, Rodriguez-Viciana P, Wennstrom S, et al. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 1997;7:63-70
41. Rincon-Arano H, Rosales R, Mora N, et al. R-Ras promotes tumor growth of cervical epithelial cells. Cancer 2003;97:575-85
42. Gawecka JE, Griffiths GS, Ek-Rylander B, et al. R-Ras regulates migration through an interaction with filamin A in melanoma cells. PLoS One 2010;5:e11269
43. Yu Y, Feig LA. Involvement of R-Ras and Ral GTPases in estrogenindependent proliferation of breast cancer cells. Oncogene 2002;21:7557-68
44. Sawada J, Urakami T, Li F, et al. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 2012;22:235-49
45. Komatsu M, Ruoslahti E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med 2005;11:1346-50
46. Nakada M, Niska JA, Tran NL, et al. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 2005;167:565-76
47. Hughes PE, Renshaw MW, Pfaff M, et al. Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 1997;88:521-30
48. Zhang Z, Vuori K, Wang H, et al. Integrin activation by R-ras. Cell 1996; 85:61-69
49. Suzuki J, Kaziro Y, Koide H. Positive regulation of skeletal myogenesis by R-Ras. Oncogene 2000;19:1138-46
50. Ramocki MB, Johnson SE, White MA, et al. Signaling through mitogenactivated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis. Mol Cell Biol 1997;17:3547-55
51. Wilson MD, Ruttan CC, Koop BF, et al. ERCC1: A comparative genomic perspective. Environ Mol Mutagen 2001;38:209-15
52. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000;16:555-60